Hearing function in soft tissue sarcoma patients after treatment with carboplatin: a report from the Late Effects Surveillance System.
The aim of this study was to analyse carboplatin-induced ototoxicity in a recent study trial. Twenty patients who had received carboplatin for the treatment of soft tissue sarcoma were investigated prospectively for ototoxicity in a multi-centre trial. Hearing function was tested by audiometry. All patients but one were treated with a cumulative dose of 1500 mg/m(2), the remaining with 500 mg/m(2). We evaluated the incidence and dependencies of hearing loss, and compared hearing thresholds to those of an untreated control group (n=60). Hearing thresholds in the carboplatin treated group were only marginally poorer compared with those of the control group. After carboplatin therapy no patient (0%; 95%-KI: 0-17%) had a hearing loss >20 dB. Hearing thresholds were not dependent on age, sex or cranial irradiation. We conclude that ototoxicity after carboplatin was low in our group of patients.
Stöhr
W
W
LESS Center, University Hospital for Children and Adolescents, Department of Pediatric Oncology, Erlangen, Germany.
Langer
T
T
Kremers
A
A
Brecht
I
I
Treuner
J
J
Dinnesen
A
A
Beck
J D
JD
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001299:Audiometry; D016190:Carboplatin / Q000009:adverse effects*; D002648:Child; D034381:Hearing Loss / Q000209:etiology*; D006801:Humans; D015994:Incidence; D011446:Prospective Studies; D012509:Sarcoma / Q000150:complications / Q000188:drug therapy*
D000970:Antineoplastic Agents; D016190:Carboplatin